Journal
EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 428, Issue 3, Pages 365-369Publisher
ELSEVIER
DOI: 10.1016/S0014-2999(01)01280-8
Keywords
airway; glucocorticoid; dexamethasone; interleukin-1 beta; NGF (nerve growth factor); neurotrophin; inflammation; asthma
Categories
Ask authors/readers for more resources
Nerve growth factor (NGF) has recently been presented as a possible effector of inflammation and bronchial hyperresponsiveness. However, the production of NGF in human airways as well as the regulation of its expression by inflammatory cytokines and glucacorticoids have received little attention. A549 epithelial cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% foetal bovine serum, and starved for 24 h. The effect of the pro-inflammatory cytokine interleukin-1 beta (1-30 U/ml), and of the glucocorticoid dexamethasone (1 muM) on NGF secretion was studied and quantified by enzyme-linked immunosorbent assay (ELISA). In addition, NGF production within the cells was visualized by immunocytochemistry. Under basal conditions, A549 cells produced and secreted NGF (12.6 +/- 2.0 pg/ml). Stimulation by interleukin-1 beta for 24 h induced a dose-dependent increase in NGF production (maximal at 10 U/ml with 59.6 +/- 3.5% increase, P < 0.05). Dexamethasone (1 muM) markedly reduced the constitute NGF secretion by 44.9% (7.0 +/- 2.1 pg/ml, P < 0.001). In addition, the interleuk-in-1 beta -stimulated NGF secretion was inhibited to approximately the same low level (8.5 +/- 2.5 pg/ml, P < 0.001). In conclusion, we here report that human airway A549 epithelia] cells are capable of producing NGF. This production is positively regulated by the pro-inflammatory interleukin-1 beta, and negatively regulated by dexamethasone. (C) 2001 Published by Elsevier Science B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available